The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
The latest projects newly into human trials include BNT3212.
A common mutation comes into play for PRMT5 inhibition.
Tolerability could decide first-line therapy in EGFRm disease.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
